SAN FRANCISCO, December 10, 2013 -  Invitae Corporation, a genetic diagnostics company, today announced the completion of a $40 million Series E financing. Invitae will use the financing to accelerate the ongoing development of the company’s clinical genetic tests for hereditary disorders, including oncology, neurology and pediatric medicine. Invitae will also focus on expanding to international markets. Investors participating in the Series E round include Genomic Health, Inc. (NASDAQ: GHDX), Randy Scott, Thomas McNerney & Partners, Redmile Group, Genesys Capital, Casdin Capital, among others. “Invitae is making significant progress in expanding our genetic testing services and executing on our business plan.  With the support of our new and existing investors, this financing will allow us to expand our offering of genetic tests and build on our commercial capabilities,” said Randy Scott, PhD, founder and chief executive officer of Invitae. “This financing will help us

SAN FRANCISCO, November 26, 2013 – Invitae Corporation, a genetic diagnostics company, today announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients through its genetic testing services.  Invitae has been named a defendant in a lawsuit filed by Myriad Genetics, Inc. regarding Invitae’s BRCA and MUTYH genetic tests. Invitae disagrees with the allegations of the lawsuit and plans to vigorously defend itself against the lawsuit, which it believes has no merit.  Earlier this year, the Supreme Court ruled that naturally occurring DNA and the information it encodes cannot be patented (Assn’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 [2013]) and thus ushered in a new era of personalized medicine.  This followed on a prior Supreme Court ruling establishing that naturally occurring biological correlations were not patentable subject matter (Mayo Collaborative

Presentation at ASCO Breast Symposium demonstrates that next-generation DNA sequencing technology accurately identifies BRCA 1 and 2 mutations and multi-gene testing adds value beyond BRCA 1 and 2 for cancer patients. San Francisco, CA, September 07, 2013. Invitae, Inc., a genetic information company, today announced the results of a study conducted in collaboration with Stanford University assessing hereditary breast and ovarian cancer risk using a multi-gene next-generation sequencing panel. The results showed that analysis of BRCA1/2 mutations produced results concordant with prior clinical testing and also identified additional pathogenic variants in genes other than BRCA1/2. The study was presented by Allison Kurian, M.D., assistant professor of Medicine (Oncology) and Health, Research and Prevention and the associate director of the Breast Cancer Genetics Clinic at Stanford, during the Poster Discussion Session A at the American Society of Clinical Oncology (ASCO) Breast

Link:  http://diario.latercera.com/2013/06/12/01/contenido/tendencias/16-139079-9-llega-a-chile-test-genetico-que-detecta-264-enfermedades.shtml